On the other hand, Human Epidermal Growth Factor Receptor 2 negative (HER2‐negative) tumors are driven more commonly by inflammatory cytokines and metabolic pathways, but can be affected by obesity status and lipid metabolism, making it relevant to study how prognosis can differs among patients with different tumor types (Sparano et al., 2022). This evidence concerns the gene ERBB2 and neoplasm.